Clinical Efficacy of TP Regimen Combined with Bevacizumab in the Treatment of Advanced Non-small Cell Lung Cancer and its Effect on the Expression of T Lymphocyte Programmed Death Receptor 1 and Cytotoxic T Lympho-cyte-associated Antigen 4

YE Feng-jin; HE Shi-yang; WEI Xiao-mei

doi:10.3969/j.issn.1004-5775.2022.19.005

Home>Articles>Clinical Efficacy of TP Regimen Combined with Bevacizumab in the Treatment of Advanced Non-small Cell Lung Cancer and its Effect on the Expression of T Lymphocyte Programmed Death Receptor 1 and Cytotoxic T Lympho-cyte-associated Antigen 4

DOI: 10.3969/j.issn.1004-5775.2022.19.005

Clinical Efficacy of TP Regimen Combined with Bevacizumab in the Treatment of Advanced Non-small Cell Lung Cancer and its Effect on the Expression of T Lymphocyte Programmed Death Receptor 1 and Cytotoxic T Lympho-cyte-associated Antigen 4

YE Feng-jin

HE Shi-yang

WEI Xiao-mei

Machine-generated Keywords：

Publication Date：2022-10-15

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：4( 2323-2326 )

HEILONG MEDICAL JOURANL

ISSN：1004-5775

Year, Vol.(Issue)：2022,46(19)